Hennion & Walsh Asset Management, Inc. Avidity Biosciences, Inc. Transaction History
Hennion & Walsh Asset Management, Inc.
- $2.15 Billion
- Q1 2025
A detailed history of Hennion & Walsh Asset Management, Inc. transactions in Avidity Biosciences, Inc. stock. As of the latest transaction made, Hennion & Walsh Asset Management, Inc. holds 62,423 shares of RNA stock, worth $2.07 Million. This represents 0.09% of its overall portfolio holdings.
Number of Shares
62,423
Previous 76,810
18.73%
Holding current value
$2.07 Million
Previous $2.23 Million
11.69%
% of portfolio
0.09%
Previous 0.11%
Shares
8 transactions
Others Institutions Holding RNA
# of Institutions
244Shares Held
116MCall Options Held
289KPut Options Held
998K-
Janus Henderson Group PLC London, X011.4MShares$379 Million0.19% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD11.3MShares$376 Million0.04% of portfolio
-
Wellington Management Group LLP Boston, MA9.68MShares$321 Million0.06% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.24MShares$307 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY8.75MShares$290 Million4.23% of portfolio
About Avidity Biosciences, Inc.
- Ticker RNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,127,000
- Market Cap $1.73B
- Description
- Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...